EUVIMEDEUVIMED entdecken
Crossref

Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study

Geoffroy Napon, Shubha Roy, Varun Jain, Ikponmwosa Igbinigie, Karthik Rayapureddi, Aishwarya Aiyer, Tejasva Gupta

Journal of Clinical Lipidology · 2026-06 · 20 (6) · e113

DOI: 10.1016/j.jacl.2026.05.174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-06. Verfasst von Geoffroy Napon und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Napon, G., Roy, S., Jain, V., Igbinigie, I., Rayapureddi, K., Aiyer, A., & Gupta, T. (2026). Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study. Journal of Clinical Lipidology, 20(6), e113. https://doi.org/10.1016/j.jacl.2026.05.174

Vancouver

Napon G, Roy S, Jain V, Igbinigie I, Rayapureddi K, Aiyer A, et al. Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study. Journal of Clinical Lipidology. 2026;20(6):e113. doi:10.1016/j.jacl.2026.05.174

BibTeX
@article{Napon2026,
  author = {Napon, Geoffroy and Roy, Shubha and Jain, Varun and Igbinigie, Ikponmwosa and Rayapureddi, Karthik and Aiyer, Aishwarya and Gupta, Tejasva},
  title = {Atrial Fibrillation Risk with PCSK9 Inhibitors Versus Statins and Ezetimibe: A Propensity-Matched Real-World Study},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  volume = {20},
  number = {6},
  pages = {e113},
  doi = {10.1016/j.jacl.2026.05.174}
}
Kostenlos starten →